ZyVersa Therapeutics, Inc.
ZVSA
$0.6794
-$0.0306-4.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -58.75% | 40.79% | 13.11% | 2.23% | 78.81% |
| Total Depreciation and Amortization | -- | -558.82% | -83.65% | 300.00% | 102.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -45.64% | 76.17% | -1.11% | -47.68% | -97.43% |
| Change in Net Operating Assets | 523.27% | -104.90% | 135.63% | 153.57% | 9.78% |
| Cash from Operations | -44.71% | -90.04% | 66.33% | 49.32% | -35.49% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -34.23% | 267.21% | -- | -100.00% | -46.55% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 63.94% | -126.49% | -- | -- | -- |
| Cash from Financing | -29.62% | 306.39% | -- | -100.00% | -38.51% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -94.28% | 41,311.76% | 100.18% | -73.36% | -170.82% |